Fuqiang Cui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6985243/publications.pdf

Version: 2024-02-01

38	2,257 citations	18	329751
papers	citations	h-index	g-index
38 all docs	38 docs citations	38 times ranked	2438 citing authors

#	Article	IF	CITATIONS
1	Epidemiological serosurvey of Hepatitis B in Chinaâ€"Declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 2009, 27, 6550-6557.	1.7	813
2	Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992–2005 in China. Journal of Infectious Diseases, 2009, 200, 39-47.	1.9	301
3	Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases, 2017, 23, 765-772.	2.0	241
4	Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study. Vaccine, 2021, 39, 2833-2842.	1.7	120
5	Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 2013, 31, J21-J28.	1.7	117
6	Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China. International Journal of Epidemiology, 2016, 45, 441-449.	0.9	65
7	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology, 2019, 17, 1929-1936.e1.	2.4	51
8	Hepatitis B vaccination coverage among health care workers in China. PLoS ONE, 2019, 14, e0216598.	1.1	43
9	Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine, 2010, 28, 5973-5978.	1.7	37
10	Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: Results from China GAVI project final evaluation. Vaccine, 2013, 31, J36-J42.	1.7	35
11	Preventing hepatitis B though universal vaccination: Reduction of inequalities through the GAVI China project. Vaccine, 2013, 31, J29-J35.	1.7	32
12	Development, Production, and Postmarketing Surveillance of Hepatitis A Vaccines in China. Journal of Epidemiology, 2014, 24, 169-177.	1,1	32
13	A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01). Journal of Clinical and Translational Hepatology, 2020, 8, 1-8.	0.7	32
14	Origins, design and implementation of the China GAVI project. Vaccine, 2013, 31, J8-J14.	1.7	29
15	Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. International Journal of Epidemiology, 2018, 47, 1529-1537.	0.9	28
16	The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992–2006: A mathematical model analysis. Journal of Theoretical Biology, 2015, 386, 115-121.	0.8	25
17	Has the public lost confidence in vaccines because of a vaccine scandal in China. Vaccine, 2019, 37, 5270-5275.	1.7	25
18	Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China. Vaccine, 2017, 35, 4229-4235.	1.7	22

#	Article	IF	CITATIONS
19	The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004–2016. Vaccine, 2018, 36, 1279-1284.	1.7	21
20	The doses of 10 $\hat{1}\frac{1}{4}g$ should replace the doses of 5 $\hat{1}\frac{1}{4}g$ in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine, 2015, 33, 3731-3738.	1.7	18
21	Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose. Vaccine, 2011, 29, 9098-9103.	1.7	16
22	Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China. Human Vaccines and Immunotherapeutics, 2015, 11, 2061-2067.	1.4	16
23	Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System. Hepatology, 2021, 73, 1251-1260.	3.6	16
24	Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China. Human Vaccines and Immunotherapeutics, 2015, 11, 2716-2722.	1.4	15
25	Public Awareness, Individual Prevention Practice, and Psychological Effect at the Beginning of the COVID-19 Outbreak in China. Journal of Epidemiology, 2020, 30, 474-482.	1.1	15
26	Key outcomes and addressing remaining challengesâ€"Perspectives from a final evaluation of the China GAVI project. Vaccine, 2013, 31, J73-J78.	1.7	13
27	Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model. Scientific Reports, 2017, 7, 2912.	1.6	13
28	Evaluation of immunization injection safety in China, 2010: Achievements, future sustainability. Vaccine, 2013, 31, J43-J48.	1.7	11
29	Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. Medicine (United States), 2018, 97, e0484.	0.4	11
30	Progress towards elimination of mother-to-child transmission of hepatitisÂB virus infection in China: a modelling analysis. Bulletin of the World Health Organization, 2021, 99, 10-18.	1.5	10
31	Trends and Factors Associated With Risk Perception, Anxiety, and Behavior From the Early Outbreak Period to the Controlled Period of COVID-19 Epidemic: Four Cross-Sectional Online Surveys in China in 2020. Frontiers in Public Health, 2021, 9, 768867.	1.3	9
32	Willingness and SARS-CoV-2 Vaccination Coverage among Healthcare Workers in China: A Nationwide Study. Vaccines, 2021, 9, 993.	2.1	7
33	Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers. Vaccine, 2015, 33, 4093-4099.	1.7	5
34	Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China. BMJ Open, 2021, 11, e048463.	0.8	5
35	Reprint of: Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–2005. Vaccine, 2013, 31, J56-J61.	1.7	3
36	Strategies to increase timely uptake of hepatitis B vaccine birth dose. The Lancet Global Health, 2020, 8, e869-e870.	2.9	3

#	Article	IF	CITATIONS
37	Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial. Vaccine, 2021, 39, 3365-3371.	1.7	2
38	12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines, 2021, 9, 1407.	2.1	0